Contact Us
Drug Search Results
More Filters [+]

TAS-266

Alternative Names: tas-266, tas266, tas 266
Latest Update: 2012-12-12
Latest Update Note: Clinical Trial Update

Product Description

TAS266 is a novel agonistic tetravalent Nanobody® targeting the DR5 receptor. (Sourced from: https://oak.novartis.com/24267/)

Mechanisms of Action: D5 Agonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TAS-266

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTAS266X2101

P1

Terminated

Oncology Solid Tumor Unspecified

2012-09-01

22%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions